Showing 1941-1950 of 2038 results for "".
- ProtoKinetix AAGP Dry Eye Therapy Program Launchedhttps://modernod.com/news/protokinetix-aagp-dry-eye-therapy-program-launched/2477115/ProtoKinetix announces the initiation of a program testing AAGP to develop a potential therapy to treat dry eye disease (DED). AAGP has demonstrated anti-inflammatory and cytoprotective properties, and also exhibits pharmaceutical properties beneficial for topical formulations, according to a com
- NovaBay Pharmaceuticals Launches NovaSight Daily Vitamin for Ocular Health on Amazon.comhttps://modernod.com/news/novabay-pharmaceuticals-launches-novasight-daily-vitamin-for-ocular-health-on-amazon-com/2477099/NovaBay Pharmaceuticals announced the launch of NovaSight, a proprietary daily vitamin and mineral supplement specially formulated to support ocular health, on Amazon.com. NovaSight is a companion product to Avenova Direct, NovaBay’s prescription-strength lid and lash spray available on Amazon.co
- AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Programhttps://modernod.com/news/agtc-announces-stargardt-disease-as-its-second-preclinical-ophthalmology-program/2477071/Applied Genetic Technologies Corporation (AGTC), announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also includes a program targeting the dry form of age-related macular degenerat
- SightGlass Vision to Present New Data on its Novel Lenses to Control Nearsightedness in Children at 3rd World Congress of Optometryhttps://modernod.com/news/sightglass-vision-to-present-new-data-on-its-novel-lenses-to-control-nearsightedness-in-children-at-3rd-world-congress-of-optometry/2477040/SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held
- Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-pharmaceuticals-announces-interim-results-from-its-phase-1b-clinical-trial-of-akb-9778-for-primary-open-angle-glaucoma/2476991/Aerpio Pharmaceuticals announced interim results from its phase 1b clinical trial of a topical ocular formulation of AKB-9778 in development as a potential treatment for primary open angle glaucoma (POAG). The phase 1b study is an ongoing randomized, double-masked study designed to assess
- PanOptica: Anti-VEGF Eye Drop Shows Promise in Treatment of Wet AMDhttps://modernod.com/news/panoptica-anti-vegf-eye-drop-shows-promise-in-treatment-of-wet-amd/2476992/PanOptica reported positive clinical data for PAN-90806, a once-daily topical formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases, according to a company news release. At the Ophthalmology Innovation Summit at
- Ocutrx Unveils ORLenz for Surgery Visualization Technology in ARWear Headsethttps://modernod.com/news/ocutrx-unveils-orlenz-for-surgery-visualization-technology-in-arwear-headset/2476972/Ocutrx Vision Technologies is revealing a next-generation AR headset technology for surgery visualization called the ORLenz. A prototype of this technology is being formally introduced at the American Academy of Ophthalmology 2019 Conference in San Francisco. The ORLenz is a second medical device
- Ex-Shire CEO Flemming Ornskov Emerges as Galderma CEO after $10B Nestlé Spinouthttps://modernod.com/news/ex-shire-ceo-flemming-ornskov-emerges-as-galderma-ceo-after-10b-nestle-spinout/2476966/As Takeda folds in Shire, two of the Irish rare disease specialist’s former top leaders have found themselves a new home at Nestlé skin health spinoff Galderma, according to a report in FiercePharma. Flemming Ornskov, Shire’s most recent CEO before the Takeda buyout, has
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476950/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated in the equity round and provi
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476948/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated significantly in the equity r